Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences (EXAS) reported a Q2 EPS loss of $0.01, beating estimates, with revenue up 16% to $811.1 million, also exceeding expectations, and subsequently raised its FY25 revenue guidance to $3.13-$3.17 billion and adjusted EBITDA outlook. Strategically, EXAS acquired exclusive U.S. rights to Freenome’s blood-based colorectal cancer screening tests, a move seen as critical to strengthening its leadership in noninvasive CRC screening and mitigating competitive threats after its internal blood test underperformed. Despite these positive developments, EXAS stock traded down over 12%, with some analysts lowering price targets while others view the Freenome deal as a significant long-term positive and a buying opportunity.

Analysis

Exact Sciences (EXAS) reported a strong second quarter, with revenue growing 16% year-over-year to $811.1 million and an EPS loss of just $0.01, significantly beating consensus estimates for a $0.19 loss. This operational strength prompted the company to raise its full-year 2025 guidance for revenue to $3.13–$3.17 billion and for adjusted EBITDA to $455–$475 million. The central development, however, is the strategic acquisition of exclusive U.S. rights to Freenome's blood-based colorectal cancer (CRC) screening test. This move directly addresses a key investor concern following the underperformance of Exact's own internal CRC blood test, which showed a 73% sensitivity. Freenome's test demonstrates a superior 81% sensitivity and is already in the FDA submission process, effectively de-risking EXAS's pipeline and neutralizing a significant competitor. Despite these positive fundamental and strategic developments, the market reacted negatively, with the stock declining over 12%. This disconnect is mirrored in analyst sentiment, where firms like Barclays, RBC, and UBS lowered price targets, while William Blair reiterated an Outperform rating, framing the drop as a buying opportunity and highlighting the deal's long-term strategic value.

Key Decisions for Investors

• Investors should weigh the significant disconnect between the stock's 12.3% decline and the company's strong Q2 results, raised guidance, and the de-risking Freenome acquisition which strengthens its long-term competitive moat.
• The primary catalyst to monitor is the progress of Freenome's premarket application with the FDA, as a successful approval and launch will be critical to validating the acquisition and driving future growth in the blood-based screening market.
• Given the conflicting analyst ratings, with some viewing the pullback as a buying opportunity while others cut price targets, investors should assess if the strategic pivot to Freenome's superior test justifies looking past the failure of the internal program and the market's immediate negative reaction.